RxDoctor Payments Data

Michelle Park, MD

Hospice and Palliative Medicine · Marietta, GANPI 1811428667

Payments from drug & device makers

What this record shows

Medtronic accounts for 82.9% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $2,127, more than ten times the $31 reported in 2023. Among hospice and palliative medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,440in general payments, 2019–2025

Across 41 payments — averaging $59.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AstraZeneca$122
  • Scpharmaceuticals Inc.$45
  • Merck$42
  • Cvrx, Inc.$31
  • Amgen$28
  • plus $151 from 7 others

What the payments were for

  • Travel & lodging$1,28653%
  • Food & beverage$1,15547%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,440 in reported general payments places this provider in the 90th percentile of 69 hospice and palliative medicine providers in Georgia.

See all hospice and palliative medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$36,590
Medicare patients
129
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fentanyl175$27,488
Xtampza ErOxycodone Myristate14$15,752
Buprenorphine44$12,001
Oxycodone Hcl258$9,798
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl24$4,148
Morphine Sulfate ErMorphine Sulfate145$4,043
Hydromorphone Hcl119$3,415
Morphine Sulfate104$3,327
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen115$2,467
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen87$2,465
Mirtazapine129$2,449
Gabapentin120$2,385
Naloxone Hcl28$1,912
Methadone Hcl63$1,251
Pregabalin60$1,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$19$15,75214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 hospice and palliative medicine providers in Georgia.

Other hospice and palliative medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →